The latest data point for RXRX's net income in Q4'25 shows a loss of $108.1M USD, marking an improvement from the previous quarter's $162.3M USD loss in Q3'25 and a positive year-over-year (YoY) growth of 39.6%, the first such gain in the period. Over the timeframe from Q1'23 to Q4'25, net income has exhibited a consistent downward trend, with quarterly losses escalating from $65.3M USD in Q1'23 to a peak of $202.5M USD in Q1'25, before stabilizing and partially recovering in the latter half of 2025. The YoY changes reflect high volatility, starting with moderate declines around -17% to -62% in 2023, improving to near-flat or positive in mid-2024, then worsening to -122% in Q1'25 amid intensified losses, and finally turning positive in Q4'25, indicating potential stabilization efforts in the company's financial performance. This bar and line chart highlights ongoing challenges in achieving profitability, with no quarters reporting positive net income.